Aptorum Group (NASDAQ:APM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference